Evidence map›Paper›PMID 41048702›Full record

ReviewACS omega2025

Advancing Drug Delivery: Design and Applications of MOF-Polyurethane Composites for Controlled Release Systems.

Chang Yan, Shuhui Hu, Qiang Fei, Bo Zhang, Wenneng Wu

Abstract readReview
In one paragraph

Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chang YanSchool of Food Science and Engineering, Guiyang University, Guiyang, Guizhou 550005, China.
Shuhui HuSchool of Food Science and Engineering, Guiyang University, Guiyang, Guizhou 550005, China.
Qiang FeiSchool of Food Science and Engineering, Guiyang University, Guiyang, Guizhou 550005, China.
Bo ZhangShanghai Engineering Research Center of Green Energy Chemical Engineering, The Key Laboratory of Resource Chemistry of Ministry of Education, College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200234, PR China.ORCID https://orcid.org/0000-0003-0218-7641
Wenneng WuSchool of Food Science and Engineering, Guiyang University, Guiyang, Guizhou 550005, China.ORCID https://orcid.org/0000-0001-8704-226X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The design and development of controlled-release drug systems represent a pivotal area of research in modern pharmaceutical technologies. An ideal drug release system should precisely regulate both the release rate and duration of the drug, thereby enhancing therapeutic efficacy, reducing dose frequency, and minimizing adverse effects. In recent years, nanomaterials have become integral to drug delivery, with nanotechnology focusing on the design and application of nanomaterials. Metal-organic frameworks (MOFs) have emerged as promising drug carriers due to their high specific surface area, tunable porosity, and selective adsorption capabilities. However, MOFs often exhibit limited thermal stability, susceptibility to degradation, and sensitivity to acidic and basic conditions. To address these limitations, the integration of MOFs with polymers has shown promising potential. MOF-polymer composites can enhance drug loading capacity, improve drug solubility, and provide greater thermal stability while mitigating adverse reactions. Polyurethane (PU) is widely employed as a drug carrier due to its unique chemical properties and biodegradability. However, PU alone may lead to issues such as burst drug release and vulnerability to fungal colonization. Consequently, MOF-PU composites have garnered significant attention as advanced drug carriers, leveraging the synergistic properties of both materials to overcome their individual limitations. This review explores the definition, preparation methods, advantages, and application domains of MOF-PU composites, with a particular emphasis on their role as drug carriers. The objective is to provide a comprehensive reference for ongoing and future research into the utilization of MOF-PU composites in drug delivery systems.

Identifiers

PMID41048702
PMCPMC12489626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.